“And one has to wonder, again, if all the money being paid for the expensive CAR-T technologies won't be challenged by the peptide technology of Generex's AE37. CAR-T might turn out to be an expensive fad. “

That’s not quite how it works. If anything we will see NGIO also become involved in CAR-T tech, as they were just about to with the merger with Kiromic. Dr von Hofe is now in that space a Pres of AppyImmune. With his dual Pres roles can he help form a collaboration? Perhaps the tech can compliment each other.